• Y K Kang, Y H Park, B Y Ryoo, Y J Bang, K S Cho, D B Shin, H C Kim, K H Lee, Y S Park, K S Lee, D S Heo, S Y Kim, E K Cho, H Y Lim, W K Kim, J A Lee, T Y Kim, J C Lee, H J Yoon, and N K Kim.
• Department of Internal Medicine, Korea Cancer Centre Hospital, Seoul, Korea. ykkang@amc.seoul.kr
• J. Int. Med. Res. 2002 May 1; 30 (3): 220-9.

AbstractControl of nausea and vomiting is very important in determining patient compliance with cisplatin chemotherapy. A multicentre, randomized, single-blind study was conducted to compare the tolerability and efficacy of ramosetron with those of granisetron over 24 h following cisplatin administration to cancer patients. In eight study centres, a total of 194 adult patients were randomly assigned to receive either intravenous ramosetron 0.3 mg or intravenous granisetron 3.0 mg. The anti-emetic effect of ramosetron determined from the no-vomiting rate lasted longer, but there was no significant difference in the number of acute vomiting episodes or the severity of nausea between the two groups. In the tolerability evaluation, there were no statistically significant differences between the two groups, except for a higher incidence of dull headache in the granisetron group. Ramosetron and granisetron appear to have equivalent efficacy and tolerability profiles, but the effects of ramosetron on the prevention of acute vomiting in patients undergoing cisplatin chemotherapy were longer lasting.

24 keywords...

hide…